Transcription Factors Regulating Brain Development and Function {#S1}
===============================================================

Transcription factors (TFs) play a crucial role during development as well as in the adult organism. Early on during embryogenesis the precisely regulated temporal and spatial expression of TFs is required to establish the body plan laying the foundation for the different tissues as well as regulating physiological functions. The fine-tuned expression of TFs is of particular importance during development and maintenance of the brain ([@B74]). TFs not only are necessary to define the specificity of neurons but also are indispensable for generating the correct wiring among the different neuronal cells allowing the highly specialized connectivity and plasticity of the brain ([@B46]; [@B102]). Deregulation of TF expression results in a broad range of diseases including neurodevelopmental diseases like autism spectrum disorder ([@B30]) and neurodegenerative diseases like Alzheimer's, Schizophrenia and Huntington's disease ([@B32]; [@B28]; [@B107]).

Here we focus on the zinc-finger transcription factor family Bcl11 expressed mainly in the hematopoietic and the central nervous systems. The crucial role of the Bcl11 genes in brain development and function became apparent by recent reports describing patients carrying heterozygous mutations of Bcl11 and their implications in intellectual disabilities and neurological disorders ([@B33]; [@B80]; [@B63]). Emerging evidence demonstrates that Bcl11 proteins execute important functions during central nervous system development and in adult neurogenesis ([@B4], [@B5]; [@B57], [@B55],[@B56]; [@B49]; [@B91], [@B90]; [@B19]; [@B109]; [@B40]; [@B111]; [@B29]). However, the molecular mechanisms required to establish and maintain these functional connections are not yet fully understood. This review provides an overview of Bcl11 regulation of molecular mechanisms in the brain, focusing in particular on Bcl11 functions in different cortical regions, i.e., hippocampus and neocortex. A better understanding of these mechanisms could contribute to the development of therapeutic treatments to prevent and/or cure neurological disorders as proposed in recent reports ([@B23]; [@B28]).

The Bcl11 Zinc-Finger Transcription Factor Family {#S2}
=================================================

The Bcl11 genes were first identified by their functions in the immune system, Bcl11a also known as Ctip1 as a proto-oncogene and Bcl11b or Ctip2 as a tumor suppressor gene ([@B6]; [@B85]). The Bcl11 genes are Krüppel-like sequence-specific C2H2 zinc-finger transcription factors located on chromosome 11 and 12 in the mouse and 2 and 14 in humans, respectively. Bcl11 genes are highly conserved throughout evolution as was shown for the human Bcl11a gene sharing 95% homology with the mouse, chicken, and Xenopus genes and 67 and 61% homology on nucleotide and protein levels with Bcl11b, respectively ([@B85]). In addition to the C2H2 zinc-finger domains located on exon 4 of both genes, Bcl11 proteins contain several protein-protein interacting domains at their N-terminal end like the nucleosome remodeling and deacetylase (NuRD) interacting domain and a CCHC finger motif ([Figure 1](#F1){ref-type="fig"}; [@B64]). The CCHC motif unlike the DNA-binding C2H2 motif promotes dimerization and nuclear translocation allowing the transcriptional regulation of target genes as was shown for Bcl11b ([@B39]). Furthermore, analysis of heterozygous mutations of the human CCHC finger motif strongly suggests that Bcl11b functions as a dimer ([@B39]). Although no data are available so far it is most likely that the CCHC motif has a similar function for Bcl11a protein regulation.

![Mouse Bcl11 predicted protein isoforms. **(A)** Alternative splicing of Bcl11a leads to four isoforms containing 1, 3, or 6 C2H2 zinc-finger domains required for DNA-binding. Exon 1 and 2 are common to all but the Bcl11a-XS isoform containing the NuRD interacting domain and a C2HC zinc-finger domain involved in protein-protein interaction. **(B)** Alternative splicing of Bcl11b results in three isoforms containing either all four exons or lacking exon 3 or exon 2 and 3. All Bcl11b isoforms contain the C2H2 zinc-finger domains and NuRD interacting domain. Bcl11b isoform a and b retain the C2HC zinc-finger domain which is missing in isoform c.](fnmol-13-00051-g001){#F1}

Alternative splicing of Bcl11 mRNAs results in at least four isoforms of human and mouse Bcl11a as well as 2 and 3 isoforms of Bcl11b in human and mouse, respectively ([Figure 1](#F1){ref-type="fig"}). The resulting Bcl11a proteins contain none (human Bcl11a-XS, 142aa), one (mouse Bcl11a-XS, 191aa; human and mouse Bcl11a-S, 243aa), three (human and mouse Bcl11a-L, 773aa) or all six (human and mouse Bcl11a-XL, 835aa) C2H2 zinc finger domains ([Figure 1A](#F1){ref-type="fig"}; [@B85]; [@B64]). All isoforms contain the NuRD interacting and CCHC zinc-finger domains except the mouse Bc11a-XS isoform lacking both motifs ([Figure 1A](#F1){ref-type="fig"}). The human Bcl11b presents two isoforms (894aa and 823aa) containing or lacking exon 3 ([@B61]) while the mouse Bcl11b isoforms are containing all four exons (isoform a, 884aa) or lacking either exon 3 (isoform b, 812aa) or exon 2 and 3 (isoform c, 690aa) ([Figure 1B](#F1){ref-type="fig"}). All human and mouse Bcl11b/Ctip2 isoforms retain the six C2H2 zinc-finger domains as well as the NuRD interacting and CCHC domains with the exception of mouse isoform c lacking the CCHC motif ([Figure 1B](#F1){ref-type="fig"}). The isoforms are expressed to various degrees in different tissues but so far, no specific function is assigned to individual isoforms in the brain. Possible functions could include self-regulation of Bcl11 protein activity by assembling of diverse dimers and protein complexes comprised of specific isoforms or factors like the NuRD complex allowing or preventing nuclear translocation and/or DNA binding. Interestingly, early work by Nakamura et al. showed that short isoforms of Bcl11a are restricted to cytoplasm whereas longer isoforms are located in the nucleus ([@B72]) thus being compatible with a possible modulating function of the transcriptional activity of a Bcl11 protein complex.

Both Bcl11 genes are expressed during embryonic development as early as E10.5 and continuing to be expressed throughout life in several tissues like the brain, immune system, and skin ([@B60]; [@B38]; [@B117]). In the central nervous system, Bcl11 genes are expressed in the dorsal spinal cord, neocortex, hippocampus, entorhinal cortex, striatum, amygdala, and cerebellum ([Table 1](#T1){ref-type="table"}; [@B60]; [@B4], [@B5]; [@B32]; [@B49]; [@B91]; [@B19]; [@B99]; [@B109]; [@B40]; [@B111]; [@B76]). The best studied brain areas in relation to Bcl11 are the hippocampus, neocortex, spinal cord, and striatum. In the striatum Bcl11b has an important function in the differentiation of medium spiny neurons which have a critical role in motor control ([@B5]). In other brain areas like the cerebellum and entorhinal cortex both Bcl11 genes are expressed but so far, no distinct functions were determined. Expression analyses revealed a partially overlapping but also distinct expression pattern of both genes in the brain ([Figure 2](#F2){ref-type="fig"}). For example, during early corticogenesis Bcl11a and Bcl11b are co-expressed by the majority of post-mitotic neurons in the intermediate zone and cortical plate. However, already at late embryonic stages two developmental lineages emerge with mutually exclusive expression of either transcription factor, which persists into adulthood ([Figure 2](#F2){ref-type="fig"}, left panels; [@B111]). In the hippocampus on the other hand the expression pattern is established early on with an overlapping expression of both Bcl11 genes in CA1/2 regions and distinct expression of Bcl11a in CA3 and Bcl11b in the dentate gyrus, respectively ([Figure 2](#F2){ref-type="fig"}, right panels; [@B60]; [@B91]).

###### 

Expression of Bcl11a and Bcl11b in regions of the central nervous system.

  CNS region            Expression   Phenotype   References          
  --------------------- ------------ ----------- ------------ ------ -------------------------------------------------
  Neocortex             \+           \+          \+           \+     [@B60]; [@B4]; [@B19]; [@B109]; [@B111]; [@B40]
  Olfactory cortex      \+           \+          n.d.         n.d.   [@B60]
  CA1-2                 \+           \+          n.d.         \-     [@B60]; [@B91]
  CA3                   \+           \-          n.d.         \-     [@B60]; [@B91]; [@B20]
  Dentate gyrus         \-           \+          \-           \+     [@B60]; [@B91], [@B90]; [@B29]
  Entorhinal cortex     \+           \+          n.d.         n.d.   [@B99]; [@B76]
  Striatum              \+           \+          n.d.         \+     [@B5]; [@B32]
  Amygdala              \-           \+          n.d.         n.d.   [@B60]
  Thalamus              \+           \-          n.d.         n.d.   [@B60]
  Hypothalamus          \+           \-          n.d.         n.d.   [@B60]
  Inferior colliculus   \-           \+          n.d.         n.d.   [@B60]
  Cerebellum            \+           \+          n.d.         n.d.   [@B60]
  Pons                  \+           \-          n.d.         n.d.   [@B60]
  Spinal cord           \+           \+          \+           n.d.   [@B60]; [@B49]

n.d., not determined.

![Bcl11 expression in the mouse brain. Bcl11 gene expression occurs early in development continuing to adulthood as shown here for the neocortex (left panels) and the hippocampus (right panels) by immuno-histochemical staining. Bcl11a (green) and Bcl11b (red) expression are shown in the neocortex at embryonic stage 14.5 (E14.5) and postnatal stage 7 (P7) and in the hippocampus at embryonic stage 18.5 (E18.5) and postnatal stage 30 (P30).](fnmol-13-00051-g002){#F2}

Little is known about the upstream control of Bcl11 expression in the brain. Best studied is the regulation of Bcl11b expression by Satb2, a chromatin regulating protein binding to the matrix attached region (MAR) of the Bcl11b locus ([@B62]). Satb2 builds a multi-protein complex with other chromatin regulating proteins like the NuRD complex modulating the Bcl11b locus and repressing transcription in a time- and region-specific manner ([@B21]; [@B12]; [@B70]; [@B62]; [@B42]). The transcription factor Tbr1, expressed in excitatory neurons, also is involved in the regulation of Bcl11 expression during neocortex development. Yet, it remains to be determined whether Tbr1 directly regulates the Bcl11 genes ([@B44]; [@B84]; [@B35]). In contrast to the nervous system, upstream control of Bcl11 proteins has been more extensively studied in the lympho-hematopoietic system (for comprehensive review see [@B15]). In erythroid cells, for example, developmental expression of Bcl11a is regulated by the RNA-binding protein Lin28b ([@B14]). Whether similar regulatory mechanisms control the translation of Bcl11 proteins in neurons has not been investigated.

Bcl11 Regulation of Target Genes {#S3}
================================

The transcriptional regulation of target genes by Bcl11 proteins requires binding of the C-terminal zinc-finger domains to specific DNA binding motifs. Bcl11a recognizes the GGCCGGAGG motif and Bcl11b GGCCG/AG/AGG, a variation of this motif, repressing the expression of target genes independently of histone deacetylases ([@B7]). However, Bcl11 transcription factors not only act as transcriptional repressors but also as activators. This was shown for Bcl11b binding in a complex with p300 to IL-2 and Cot kinase genes in CD4^+^ T-cells recognizing TGGGC as DNA binding motif ([@B26], [@B25]). From these data one could assume that promoters of Bcl11 target genes containing the GGCCGGAGG motif are transcriptionally inhibited and promoters containing the TGGGC motif are activated by Bcl11 proteins. This was refuted by the presence of both motifs in promoter sequences of activated or repressed target genes recognized by both Bcl11 proteins ([@B49]; [@B91]; [@B109]; [@B29]). In addition, the binding of Bcl11 proteins was more efficient when both motifs were present as was shown for desmoplakin (Dsp), a direct Bcl11b target gene activated during dentate gyrus development ([@B91]), and Sema3c, directly regulated by Bcl11a ([@B109]). In the case of Sema3c the promoter sequence consists of six repeats of the combined GGCCGG and TGGGC motifs, TGGGCCGG, embedded in a 212 base pair repeat sequence ([@B109]). More recently it was shown by an unbiased *in vitro* approach that both, Bcl11a and Bcl11b zinc-finger domains bind with high affinity to a TGACCA motif ([@B65]). The different regulatory mechanisms of Bcl11 proteins suggest that the transcriptional regulation requires a binding complex consisting of Bcl11 and additional specific co-factors to either activate or inhibit the expression of particular target genes.

Bcl11 Binding Complex {#S4}
=====================

Both Bcl11 proteins were independently isolated through their interaction with the chicken ovalbumin upstream promoter transcription factor (COUP-TF) of orphan nuclear receptors ([@B6], [@B7]; [@B88]). Both proteins repress the expression of their target genes when in a complex with COUP-TF or the NuRD complex ([@B24]). NuRD complex is a major ATP-dependent chromatin remodeling complex consisting of a range of subunits like the metastasis-associated genes (MTAs) allowing the transcriptional regulation of target genes by binding tissue specific transcription factors ([@B58]; [@B54]). This was shown for the binding of the Bcl11b-NuRD complex to its target gene p57KIP2, a cyclin dependent kinase, involving co-binding of MTA2 and HDAC2 ([@B100]). The repressor function of Bcl11b is executed by binding to the MTAs via the conserved N-terminal MSRRKQ motif ([@B24]; [@B34]). Phosphorylation of the serine of the MSRRKQ motif impedes Bcl11b binding to MTAs preventing transcriptional repression of target genes ([@B34]). Furthermore, both Bcl11 proteins mediate transcriptional repression *in vitro* through recruitment of the histone deacetylase SIRT1 ([@B88], [@B89]). Moreover, Bcl11a interacts with members of the NR2E/F subfamily of nuclear receptors, through two distinct regions containing a novel signature motif (F/YSXXLXXL/Y) ([@B20]). Using a proteomics approach several Bcl11a-interacting partners were identified in erythroid cells, including components of the NuRD, LSD1/CoREST, and SWI/SNF or BAF complexes ([@B112]).

Up to now the described complex comprised of Bcl11 proteins and chromatin remodeling factors were studied mostly in the hematopoietic system which does not exclude a role of these factors in the transcriptional regulation of the nervous system. However, during neuronal development the SWI/SNF or BAF complex consisting of several subunits including the Bcl11 proteins (BAF100a/b), seems to play a more crucial role. First discovered as tumor suppressor genes involved in a range of cancers ([@B51]; [@B50]) some of the subunits carry out distinct functions during neuronal development and their dysfunction leads to neurodevelopmental disorders including intellectual disability ([@B17]). Different compositions of the BAF complex are present at different embryonic as well as neuronal differentiation and maturation stages ([@B95]; [@B94]). Regarding the role of Bcl11b in dentate gyrus development and adult neurogenesis two neuron-specific BAF family members, BAF53b and BAF170, are of specific interest. BAF170 is expressed in neuronal progenitor cells playing a role in the regulation of neurogenesis in the developing as well as the adult dentate gyrus. Loss of BAF170 expression in the hippocampus affects the pool of progenitor cells and neuronal differentiation resulting in impaired learning behavior ([@B101]). BAF53b on the other hand is expressed in post-mitotic neurons and involved in synaptic plasticity of the hippocampus and long-term memory consolidation ([@B105]; [@B106]; [@B113]). The phenotype analysis of these BAF members shows similarities to the hippocampal Bcl11b phenotype ([@B91], [@B90]; [@B29]). It would be of interest to directly determine how these BAF family members and Bcl11b interact during postnatal dentate gyrus development and adult neurogenesis.

Bcl11a Regulation of Spinal Cord and Neocortex Development {#S5}
==========================================================

Conditional mutagenesis of Bcl11a in the developing dorsal spinal cord of the mouse demonstrated impaired morphological differentiation interfering with the formation of the somatosensory circuitry within the dorsal spinal horn. This connectivity is in part established by the Wnt pathway component Frzb/Sfrp3, which was identified as the first functional downstream target of Bcl11a during CNS development ([@B49]). Bcl11a is also expressed by young post-mitotic projection neurons of the developing neocortex as early as E12.5 ([Figure 2](#F2){ref-type="fig"}, left panels). Projection neurons are born in germinal zones located near the ventricles and undergo radial migration toward the pial surface of the brain changing from a multipolar to a bipolar cell shape on the way ([@B73]). Late-born Bcl11a deficient neurons destined to settle in superficial layers fail to switch from multipolar to bipolar morphology and undergo delayed migration into the cortical plate ([@B109]). Bcl11a directly represses Semaphorin 3c (Sema3c) expression, which is upregulated in the intermediate zone of the Bcl11a deficient neocortex. Normalization of Sema3c expression in Bcl11a deficient projection neurons restores radial migration in these cells. Moreover, Bcl11a binds to a DNA repeat in the second intron of Sema3c that conveys transcriptional repression. Thus, Bcl11a acts through Sema3c as an important regulator of radial migration in developing cortical projection neurons ([@B109]).

Although Bcl11a deficient superficial neurons appear to be correctly specified at birth, changes were observed in the populations of projection neuron subtypes within Bcl11a deficient deep cortical layers. Here, supernumerary subcerebral neurons are born at the expense of callosal and corticothalamic neurons ([@B109]; [@B111]). In contrast, overexpression of Bcl11a in deep cortical layers suppresses subcerebral neuron identity and projection toward the spinal cord. Thus, Bcl11a appears to specify subtype identity in deep-layer cortical neurons, preventing corticothalamic and callosal projection neurons to acquire a subcerebral projection neuron identity ([@B111]). Contradicting this model, it was shown that reducing the expression levels of Bcl11a in deep cortical layers by small hairpin RNA leads to increased Tbr1 expression and decreased subcerebral neuron fate ([@B19]). This discrepancy could be explained by residual expression of Bcl11a after knockdown as compared to genetic loss of function and highlights the general importance of balanced gene dosage of transcription factors for specification of neuron subtypes. As neocortical development proceeds, Bcl11a becomes refined and highly expressed in primary sensory areas across cortical layers VI, IV, and deeper II/III in wildtype brains ([@B40]). By using a transcriptomic approach, [@B40] showed that area-specific genes, which are normally enriched in wildtype sensory cortex, are downregulated, whereas genes typical for the motor cortex are upregulated in Bcl11a deficient sensory cortex. This in turn leads to disturbances of cortical connectivity, including cortico-cortical and corticofugal axonal projections ([@B40]). In summary, Bcl11a plays an important role for various aspects of cortical development, including specification of early-born deep-layer projections neurons, radial migration and postnatal morphological differentiation of late-born superficial-layer projection neurons, and acquisition of cortical sensory area identity. Still, our knowledge about the specific downstream genetic programs, which are transcriptionally regulated by Bcl11a, is incomplete and awaits further investigation.

Bcl11b and Hippocampal Development {#S6}
==================================

The hippocampus consisting of the dentate gyrus (DG), the Cornu ammonis (CA), and the subiculum has an important function in learning and memory as well as emotional behavior ([@B36], [@B37]; [@B103]). The DG, functioning as the primary gateway for input information, develops mainly postnatally under the control of stage-specific transcription factors ([@B46]; [@B102]; [@B16]). Hippocampal Bcl11b expression is first detected at E15, in the cornu ammonis and few cells of the developing dentate gyrus anlage, expanding to the suprapyramidal blade by E18. During postnatal development and throughout life Bcl11b is expressed in post-mitotic cells of the dentate gyrus as well as the pyramidal cells of the CA1 and CA2 regions but not the CA3 region ([Figure 2](#F2){ref-type="fig"}, right panels; [@B91]). In the DG Bcl11b regulates progenitor cell proliferation, differentiation and maturation of neurons as well as their functional integration ([@B91], [@B90]; [@B29]). Although Bcl11b is selectively expressed in post-mitotic granule cells, loss of Bcl11b expression affects progenitor cell proliferation suggesting a non-cell autonomous regulatory mechanism. In addition, deletion of Bcl11b causes an arrest of granule cell differentiation at the mitotic to post-mitotic transition stage implying a cell autonomous regulation of cell differentiation. Unexpectedly, Bcl11b activates the transcription of desmoplakin, a cell adhesion molecule, in dentate gyrus granule cells ([@B91]). Comparing the Bcl11b and desmoplakin phenotype suggests desmoplakin to be responsible for cell-cell communication to regulate proliferation and differentiation as well as spine formation ([@B91]).

Ablation of Bcl11b during postnatal development causes a dramatic mossy fiber phenotype implying a role in axon outgrowth and pruning ([@B91]). Mossy fibers, the axons of dentate gyrus granule cells, are required to relay information from the DG to the CA3. During development a number of axon guidance molecules including ephrins and semaphorins are involved to ensure a functional DG-CA3 circuit by directing the outgrowth as well as the pruning of mossy fibers ([@B10]; [@B82]; [@B66]). Bcl11b directly represses Sema5b expression which was shown to be involved in the elimination of excess mossy fiber synapses ([@B75]; [@B29]). Although Bcl11b is not expressed in CA3 the loss of Bcl11b expression in the dentate gyrus causes fewer thorny excrescences, the postsynaptic partner of mossy fiber boutons of CA3 pyramidal neurons ([@B91]).

Bcl11b and Adult Hippocampal Neurogenesis {#S7}
=========================================

Since Altman and colleagues first reported about adult neurogenesis in the 1960s ([@B3]) its existence was often questioned. While over the years strong evidence accumulated of adult neurogenesis occurring in rodents it has been more challenging to unambiguously demonstrate its existence in the human brain. A recent report declaring the stop of neurogenesis in childhood sparked again the discussion about adult-born neurons in humans ([@B96]). However, adjusting the lifespan of the different species and methods used lead to the conclusion that adult neurogenesis occurs in all species but drops to very low rates during postnatal life ([@B97]; [@B53]; [@B18]; [@B52]; [@B71]; [@B92]). Numerous publications examining adult neurogenesis in rodents demonstrate an important function for newborn neurons in the adult or aged brain in regard to learning and memory as well as stress behavior ([@B36], [@B37]; [@B103]; [@B48]).

The Bcl11b adult-induced mouse model provides further evidence for the importance of adult neurogenesis ([@B90]). Adult-induced Bcl11b mutants exhibit similarities to the postnatal phenotype with the exception of the mossy fiber tract which appeared not to be affected ([@B91], [@B90]). However, a closer examination of the DG-CA3 connectivity revealed a reduced number of synapses and ultra-structural changes of the adult-induced Bcl11b mutant boutons which are mirrored by a dramatic decline of long-term potentiation as early as 2 weeks after induction of the mutation weeks before the onset of apoptosis and arrest of differentiation ([@B29]). These data demonstrated for the first time that transcriptional mechanisms directly regulate synaptic homeostasis independent of activity.

Given the Bcl11b mutant phenotype in mice, specifically changes of the dentate gyrus-CA3 connectivity, strongly suggests behavioral consequences. Indeed, analyzing hippocampal specific behavior of Bcl11b mouse models demonstrated impairment of spatial learning and working memory ([@B91], [@B90]). These behavioral changes are more pronounced in the conditional than the adult-induced Bcl11b mutant most likely due to the more severe phenotype of the DG-CA3 circuitry. It seems that once established the mossy fiber tract is more resistant to interferences, e.g., loss of Bcl11b expression, in contrast to the developing mossy fiber tract. In addition, Bcl11b might execute different functions during postnatal development of the dentate gyrus and in the adult hippocampus. It seems that Bcl11b no longer plays such a crucial role in the regulation of progenitor cell proliferation in the adult hippocampus but is required for the maintenance of the existing and integrated neurons ([@B90]). Although the DG-CA3 circuitry is affected in adult-induced Bcl11b mutants it appears that the remaining dentate gyrus granule cells are able to compensate for the loss preventing a more striking behavioral phenotype.

Bcl11 Transcription Factors and Neurological Disorders {#S8}
======================================================

Recent reports examining patients carrying heterozygous Bcl11 mutations not only revealed severe defects of the immune system but also neurodevelopmental disorders including intellectual disabilities ([@B33]; [@B80]; [@B63]; [@B93]; [@B114]; [@B78]). In the case of Bcl11a the mutations analyzed so far reside at the amino terminal end most likely preventing protein-protein interactions, e.g., homodimerization for nuclear localization and complex building of factors required for DNA binding, leading to impaired transcriptional regulation ([@B33]). In addition, the 2p15-16.1 microdeletion syndrome affecting also the Bcl11a gene leads to brain abnormalities like hypoplasia of the corpus callosum, neocortex, amygdala as well as hippocampus ([@B81]; [@B41]; [@B79]; [@B11]; [@B9]). Moreover, Bcl11a was reported by several large-scale exome sequencing studies to be a candidate risk gene for neuropsychiatric disorders, including intellectual disability and autism spectrum disorders (ASDs) that are linked with impaired neocortical development ([@B27]; [@B47]; [@B30]; [@B86]; [@B31]). Reports concerning Bcl11b described frameshift, nonsense and missense mutations as well as chromosomal rearrangements located in the center part or the C-terminal end of the protein most likely affecting the DNA binding capacity ([@B80]; [@B63]). These mutations resulted in multisystem anomalies, immune deficiency, developmental delay as well as intellectual disabilities with varying degrees of severity probably depending on the mutation site ([@B80]; [@B63]).

Notably, autism spectrum disorders could also be caused by impaired remodeling of the BAF complex ([@B83]; [@B106]; [@B94]; [@B2]). Bcl11 proteins as part of the BAF complex are associated with autism spectrum disorder and schizophrenia ([@B13]; [@B33]; [@B94]). During neuronal development specific BAF complexes are assembled at different stages: embryonic stem cell (esBAF), progenitor (pnBAF), and neuronal BAF (nBAF) complexes. These complexes differ by the composition and ratio of specific subunits. As an example, BAF53a in pnBAF is replaced by BAF53b in nBAF complexes which coincides with the transition from mitotic to post-mitotic stages of the cell ([@B2]). Failure of this replacement of factors results in impaired progenitor cell proliferation and dendritic morphogenesis as well as learning and memory impairment ([@B105]; [@B104]).

Examining the adult and aging human as well as rodent brain suggests Bcl11b to be involved in a number of neurodegenerative disorders like Alzheimer's disease (AD) ([@B32]; [@B23]; [@B28]; [@B67]), Huntington's disease (HD) ([@B32]; [@B1]), schizophrenia ([@B108], [@B107]), and amyotrophic lateral sclerosis (ALS) ([@B22]; [@B61]). One common feature of neurodegenerative diseases including HD, AD, Parkinson disease as well as ALS, is the loss of synapses ([@B45]; [@B8]; [@B87]). Synapses are the most crucial structure for neuronal communication and loss of synapses, in particular alterations of the presynaptic terminal are highly indicative of neural diseases ([@B8]). In addition, deregulated synapse elimination or pruning during development leads to neurodevelopmental diseases like ASD and schizophrenia ([@B77]; [@B98]). Bcl11b is required for the formation and maintenance of synapses during development as well as in adulthood in the hippocampus possibly involving a member of the C1ql gene family, C1ql2 ([@B91]; [@B29]). C1q-like proteins (C1ql1-4), a subgroup of the C1q gene family, are involved in the formation and stabilization of synapses acting as extracellular scaffolding proteins and regulating synaptic activity by establishing among others postsynaptic kainate-type glutamate receptor complexes ([@B69]; [@B68]; [@B115], [@B116]). Elimination of non-functional synapses on the other hand is mediated by microglia and other members of C1q family proteins ([@B98]; [@B45]; [@B43]; [@B59]; [@B87]; [@B110]). Loss of Bcl11b expression might contribute to the onset of neurological disorders by direct prevention of synapse formation and maintenance and indirect activation of synapse elimination by microglia and C1q proteins.

Concluding Remarks {#S9}
==================

In the nervous system Bcl11 proteins regulate multitudes of signaling pathways during development, maturation and aging establishing and maintaining a functional brain circuitry. Both Bcl11 proteins are expressed in a number of diverse cells regulating their proliferation, differentiation and maturation by conserved mechanisms. However, numerous unanswered questions remain concerning the molecular mechanisms of Bcl11 regulation. How do the widely expressed Bcl11 genes direct the development and maintenance of highly specialized cells like projection neurons in the brain? Most importantly, what are the partners of Bcl11 in these processes, e.g., downstream genes and co-factors of specific binding complexes to ensure the specific fate of cells? Answers could be provided by comparative transcriptome analyses of single cells determining target genes and signaling pathways as well as proteomics to determine the composition of specific protein complexes involved. Interestingly, human Bcl11 mutations result in neurodevelopmental impairments including autism spectrum disorder. Reiterating human Bcl11 mutations in mouse models could further contribute to a better understanding of the involved molecular mechanisms. [@B63] introduced genetically human-type Bcl11b mutations into the mouse and compared the phenotypic consequences in both species. They could demonstrate that human and mouse Bcl11b mutations have comparable regulatory functions in mouse brain development ([@B63]). Thus, the mouse model provides a promising approach to determine in depth Bcl11a/b dependent regulatory pathways in the brain.
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